Business Wire

VIFOR-PHARMA

26.5.2019 09:02:08 CEST | Business Wire | Press release

Share
Pioneering Project for Pharmaceutics – Vifor Pharma and the University of Basel are Jointly Establishing the World’s First Research Professorship for Nanopharmaceutical and Regulatory Science

Nanopharmaceutics promises ground-breaking innovation in the development of medicines:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190526005014/en/

  • The Vifor Pharma Group is endowing two professorships for Nanopharmaceutical and Regulatory Science at the University of Basel
  • The commitment by Vifor Pharma and the University of Basel is aimed at ensuring Switzerland has the specialist knowledge and equipment needed to compete globally in this important emerging area of life sciences
  • With this decision, Vifor Pharma is demonstrating its commitment to Switzerland as a world-leading location for pharmaceutical research and development

Nanomedicines are playing an increasingly important role in the development of innovative new medications. These drugs are able to overcome specific cellular barriers in the human body with a view to targeting their effect even more precisely. Nanopharmacy therefore promises to help advance medical science and bring significant benefit to patients.

At present, however, researchers are only just beginning to acquire the in-depth scientific insights needed for a fundamental understanding of the development of nanomedicines, their applications and especially the regulatory requirements for their approval across Europe and worldwide. Likewise, there is a lack of experts with the necessary specialist knowledge – and these experts are urgently needed in industry, at regulatory authorities and in medical practice, including in Switzerland. As with other areas of cutting-edge research, this will take the form of a global race: those able to present findings as quickly as possible will be able to assert themselves as a centre of excellence in nanopharmaceutics.

Spread over 10 years, the commitment of CHF 10 million by the Vifor Pharma Group is intended to establish the field of nanopharmacy research at the University of Basel and to support the training of corresponding experts. The newly-created professorships in Nanopharmaceutical and Regulatory Science will be based at the Department of Pharmaceutical Sciences. There are also plans to establish and develop an internationally renowned Excellence Platform for the development, authorisation and application of nanopharmaceuticals, as well as the training of experts in the field.

Vifor Pharma views its contribution as start-up funding for this Excellence Platform, which is supported and jointly endorsed by stakeholders from academia, industry and public authorities. The aim is for the platform to both focus on research and teaching, and also to seek out international partnerships, organise conferences and incorporate additional sponsors with a view to becoming a leading international centre for nanopharmacy. “In order to make rapid progress in nanopharmaceutics, we’re reliant on clear and scientifically sound parameters for authorisation and patient safety,” says Etienne Jornod, Executive Chairman of the Board of Directors at Vifor Pharma. “The field of nanopharmacy is growing quickly, and it’s important to secure a leading position in this innovative area of medicine with the help of qualified experts. That’s why we want to help ensure that Switzerland establishes a strong research foundation in this emerging area of pharmaceutical development.”

For the University of Basel, this collaboration marks an important step in the further development of its life sciences focal area. “We’re proud to be able to develop this promising field of research in collaboration with a major industrial partner,” says Professor Andrea Schenker-Wicki, President of the University of Basel. “The crucial thing here is that we’re not only developing the scientific foundations, but also training the experts who will take this knowledge with them into industry and public authorities.” It is, she says, a key step for Basel and Switzerland in terms of their ability to compete on the international stage.

Vifor Pharma Group is a global pharmaceuticals company headquartered in Switzerland. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. The Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. The Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); Relypsa; and OM Pharma. The Vifor Pharma Group is listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit www.viforpharma.com .
In Switzerland Vifor Pharma has four production and research & development sites where the vast majority of medications are produced. Together with company headquarters, these sites employ over 1,300 people in Switzerland. The affiliate Vifor Pharma Switzerland is operating out of Villars-sur-Glâne in the French speaking part of the country.

The University of Basel has an international reputation of outstanding achievements in research and teaching. Founded in 1460, the University of Basel is the oldest university in Switzerland and has a history of success going back over 550 years.
As a comprehensive university offering a wide range of high-quality educational opportunities, the University of Basel attracts students from Switzerland and the entire world, offering them outstanding studying conditions as they work towards their bachelor’s, master’s or PhD degrees. Today, the University of Basel has around 13,000 students from over a hundred nations, including 2,800 PhD students. The University of Basel has seven faculties covering a wide spectrum of academic disciplines. At the same time, the university has positioned itself amidst the international competition in the form of five strategic focal areas: Life Sciences, Visual Studies, Nanosciences, Sustainability and Energy Research and European and Global Studies. In international rankings, the University of Basel is regularly placed among the 100 top universities in the world thanks to its research achievements.
The University of Basel has deep roots in the economically powerful and culturally rich Basel region. The university also works closely with domestic and international partners to make relevant contributions to the advancement of the sciences and society. This also means that the University of Basel pays particular attention to aspects of sustainability, equal opportunity and knowledge transfer.

Contact:

Media Relations Vifor Pharma Heide Hauer Head of Corporate Communications +41 58 851 80 87 media@viforpharma.com

Media Relations University of Basel Matthias Geering Leiter Public Affairs, Kommunikation & Marketing +41 61 207 35 75 / +41 79 269 70 71 matthias.geering@unibas.ch

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings7.8.2026 19:48:00 CEST | Press release

An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accr

Coulson Aviation Canada Acquires 10 Former RCAF Hercules, Doubling C-130H Fleet7.8.2026 19:16:00 CEST | Press release

Canadian-led expansion will build the world’s largest and most capable C-130 airtanker fleet Coulson Aviation Canada, the Canadian division of Coulson Aviation, has acquired 10 former Royal Canadian Air Force CC-130H Hercules aircraft from the Government of Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260807019094/en/ Britton Coulson, left, and Wayne Coulson stand in front of one of 10 former Royal Canadian Air Force CC-130H Hercules aircraft recently acquired by Coulson Aviation from the Government of Canada. At right is a Coulson C-130H outfitted for aerial firefighting with the company’s proprietary RADS-XXL retardant delivery system, capable of carrying up to 4,000 U.S. gallons, or more than 15,000 litres, of water or fire retardant. The acquisition doubles Coulson’s global C-130H fleet to 20 aircraft, expanding its capacity to build the world’s largest C-130 airtanker fleet. The acquisition doubles Coulson’s g

Energy Vault Announces Strategic Agreement to Deploy 1.25 GW of Integrated Power Infrastructure for Hyperscaler AI Data Center with Leading Power Generation EPC Deploying Caterpillar Gensets7.8.2026 18:16:00 CEST | Press release

Partnership combines Energy Vault's FEOC-compliant BESS, grid-forming PCS, and AI infrastructure control software with partner’s turnkey power generation, Caterpillar gensets and EPC capabilitiesReference architecture delivers firm grid-independent power, essential grid stabilization and load balancing to deliver modular, scalable, gigawatt-scale AI campuses with "always-on" availabilitySecond strategic framework agreement together advances Energy Vault's AI infrastructure strategy and establishes a repeatable “speed-to-power” deployment platformInitial 1.25 GW is backed by a hyperscaler customer contract for deployment in TexasEnergy Vault expects a revenue impact of ~$500 - $600 million in 2H 2026 and 2027, which will be discussed during the upcoming earnings call on August 11, 2026 Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault"), a global leader in sustainable energy infrastructure, today announced the execution of a strategic commercial agreement under which Energy Vault

SES Advances Next-generation MEO Strategy Following Successful Completion of IRIS² Rendez-vous 17.8.2026 10:52:00 CEST | Press release

IRIS² expands SES's differentiated MEO architecture while supporting Europe's secure, sovereign multi-orbit connectivity ambitions SES today announced the successful completion of Rendez-vous 1 (RDV1) under the Infrastructure for Resilience, Interconnectivity and Security by Satellite (IRIS²) programme, marking a key milestone in the programme's implementation phase and reinforcing Europe's path towards sovereign, resilient and secure satellite connectivity. The successful completion of RDV1 confirms the programme's readiness to move forward with implementation and provides greater visibility on the long-term scope, performance and economics of the MEO segment. SES's expected capital commitment for the MEO segment is up to €1.35 billion, reflecting current programme scope, while maintaining the deployment of 18 MEO satellites and the targeted service entry in 2030. SES’s share of the investment in the IRIS² programme for 2026 is included in SES’s FY26 Capex outlook as previously commun

Allianz Delivers Record Result and Is Well on Track to Achieve Its Targets7.8.2026 07:10:00 CEST | Press release

2Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806509750/en/ Oliver Bäte, Chief Executive Officer of Allianz SETotal business volume at 45.6 billion euros, an internal growth of 5.7 percent1, with contributions from all segments. Asset Management delivers excellent growth. Operating profit rises 10.6 percent to a record level of 4.9 billion euros. Shareholders’ core net income at 2.6 billion euros; 12.7 percent below last year. Adjusted for a divestment gain last year and offsetting measures following the sale of the stake in our Indian JVs, underlying growth is strong at 10 percent. 6M 2026Total business volume at 98.6 billion euros, an internal growth of 4.3 percent1, driven by Property-Casualty and especially Asset Management. Operating profit rises 8.6 percent and reaches a record level of 9.4 billion euros. Shareholders’ core net income advances 15.5 percent to 6.4 billion euros. Adjusted for divestment effec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye